A recent academic case study, published on April 22, examined using Amgen Inc’s AMGN Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis.
The findings have implications for Cullinan Therapeutics Inc’s CGEM CLN-978, a similar CD19xCD3 bispecific T-cell engager.
Most recently, Cullinan Therapeutics, formerly Cullinan Oncology,…

#amgenincs#amgnblincyto#cullinantherapeutics#cullinanoncology#cln978#sle#williamblair#phase1